Steven Rapp
Cardiovascular Disease · Aventura, FLNPI 1174588354
Payments from drug & device makers
What this record shows
That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
$1,613,783in research payments, 2019–2025
Across 411 payments — averaging $3926.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$907K
- Boehringer Ingelheim International GmbH$307K
- Alnylam Pharmaceuticals Inc.$132K
- AstraZeneca$122K
- Boehringer Ingelheim Pharma GmbH & Co.kg$81K
- Astrazeneca UK Limited$46K
- plus $19K from 1 others
How this compares
$0 in reported general payments places this provider in the 0th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Aventura
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.